LILLY Financials
| 532457BH0 | 98.03 1.71 1.71% |
LILLY |
Please note, the presentation of LILLY's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, LILLY's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of LILLY's management manipulating its earnings.
LILLY Bond Summary
LILLY competes with Warner Music, Diageo PLC, Motorsport Gaming, Altria, and Meta Platforms. Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Companys products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Companys new molecular entities , which are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Ixekizumab, Necitumumab,, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab.| Instrument | USA Bond |
| Exchange | Bond Exchange |
| ISIN | US532457BH00 |
| Sector | Manufacturing |
| Industry | Industrial |
| Benchmark | Dow Jones Industrial |
| Website | www.lilly.com/ |
LILLY ELI 275 Systematic Risk
LILLY's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. LILLY volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on LILLY ELI 275 correlated with the market. If Beta is less than 0 LILLY generally moves in the opposite direction as compared to the market. If LILLY Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one LILLY ELI 275 is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of LILLY is generally in the same direction as the market. If Beta > 1 LILLY moves generally in the same direction as, but more than the movement of the benchmark.
LILLY March 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of LILLY help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of LILLY ELI 275. We use our internally-developed statistical techniques to arrive at the intrinsic value of LILLY ELI 275 based on widely used predictive technical indicators. In general, we focus on analyzing LILLY Bond price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build LILLY's daily price indicators and compare them against related drivers.
| Information Ratio | 0.345 | |||
| Maximum Drawdown | 1.66 | |||
| Value At Risk | (0.23) | |||
| Potential Upside | 0.2123 |
Other Information on Investing in LILLY Bond
LILLY financial ratios help investors to determine whether LILLY Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in LILLY with respect to the benefits of owning LILLY security.